-
02:05:58 PM

BMRN Stock News

09/15/23 9:29 AM
Nasdaq : BMRN
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
U.S. Food and Drug Administration PDUFA Target Action Date for Supplemental New Drug Application for VOXZOGO for Children Under 5 is Oct. 21, 2023. The U.S. Food and Drug Administration has also set a PDUFA Target Action Date of Oct. 21, 2023, for the company's Supplemental New Drug Application for VOXZOGO to expand treatment in the United States to include...
RHEA-AI
neutral
07/31/23 4:03 PM
Nasdaq : BMRN
earnings
BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
VOXZOGO ® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 Guidance Pivotal Program with VOXZOGO in New, Potential Second Indication, Hypochondroplasia, to Begin in the Fourth Quarter of 2023 U.S. Approval of ROCTAVIAN™ Received in the Second Quarter and Commercial Launch Underway; Commercial Launch in...
RHEA-AI
neutral
06/29/23 2:34 PM
Nasdaq : BMRN
fda approval
U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that the United States Food and Drug Administration approved ROCTAVIAN™ gene therapy for the treatment of adults with severe hemophilia A without antibodies to...
RHEA-AI
neutral
06/22/23 8:00 AM
Nasdaq : BMRN
conferencesclinical trial
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress
BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, today announced it will present new data from the ROCTAVIAN™ gene therapy clinical trial program. These data will be shared this week in four oral presentations and two posters at the 31st...
RHEA-AI
neutral